STOKE PARK COUNTRY CLUB, one of the most recognised clubs in England, has announced its closure for two years from August 2 to carry out restoration work, a report said.
The five-star hotel that was bought by Indian industrialist Mukesh Ambani just over a month ago for £57 million and will reopen in the summer of 2023, The Telegraph said.
Its golf club and estate will shut on October 18.
The announcement has angered many of its 2,500 members, who have struggled to enjoy its facilities of 27-hole championship course, 13 tennis courts, three restaurants, gymnasium, spa and 49 luxurious rooms during the coronavirus pandemic.
Members, who pay more than £4,000 a year in membership fees, fear the club could become Ambani’s private residence, the newspaper said.
"It's all up in the air. There's talk of it being made into a private residence. A lot of the golf clubs in the UK are being bought over by very rich people from abroad – it's strange," said Des Folliard, a former club golf captain who has played there for 23 years.
The closure will hit the Boodles Challenge, an international five-day tennis exhibition held in the week before Wimbledon, the newspaper said.
Stoke Park will also scale down its 160 staff, with those leaving being "properly compensated for their dedicated service", a club spokesman said.
"The new owners of Stoke Park, Reliance Industries Limited, are making a major investment into the estate and are committed to preserving Stoke Park's rich heritage,” he added.
He added that members remained the "beating heart" of Stoke Park and they look forward to welcoming them back to share a "glorious future".
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.